8-K: Aquestive Therapeutics Reports Full Year 2023 Results and Provides Business Update

Aquestive Therapeutics announced its full year 2023 financial results, reporting $50.6 million in revenue and a non-GAAP adjusted EBITDA loss of $11.6 million, while also providing updates on key pipeline developments.

Summary

• Aquestive Therapeutics reported full year 2023 revenue of $50.6 million, a 6% increase compared to $47.7 million in 2022, or a 26% increase excluding the impact of prior year proprietary sales of Sympazan.
• The company's non-GAAP adjusted EBITDA loss for 2023 was $11.6 million, a significant improvement from the $35.3 million loss in 2022.
• The net loss for the full year 2023 was $7.9 million, or $0.13 loss per share, compared to a net loss of $54.4 million, or $1.12 loss per share in 2022.
• Manufacturing volumes reached approximately 45 million doses in the fourth quarter of 2023, compared to approximately 37 million doses in the fourth quarter of 2022.
• The company reaffirmed the expected release of topline pivotal clinical data for Anaphylm in March 2024 and the anticipated FDA decision on the Libervant application in April 2024.
• Aquestive provided full year 2024 financial guidance, expecting total revenue between $48 million and $51 million and a non-GAAP adjusted EBITDA loss between $22 million and $26 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant improvements in financial performance and progress in key pipeline developments. However, the company still faces risks and challenges, including the need for further FDA approvals and the potential for future losses.

Positives

• The company experienced a 26% increase in revenue for 2023, excluding the impact of prior year proprietary sales of Sympazan.
• Aquestive significantly reduced its non-GAAP adjusted EBITDA loss from $35.3 million in 2022 to $11.6 million in 2023.
• The company's net loss per share improved from $1.12 in 2022 to $0.13 in 2023.
• Aquestive is on track for the submission of the Anaphylm NDA before the end of 2024.
• The company has a PDUFA action date for Libervant in April 2024.
• Aquestive has a strong cash position of $23.9 million as of December 31, 2023.

Negatives

• Aquestive reported a net loss of $7.9 million for the full year 2023.
• The company anticipates a non-GAAP adjusted EBITDA loss between $22 million and $26 million for 2024.
• The 2024 revenue guidance of $48 to $51 million is lower than the 2023 revenue of $50.6 million.
• Libervant's approval for patients 12 years and older is blocked by orphan drug market exclusivity until January 2027.

Risks

• There are risks associated with the development of Anaphylm, including potential delays or changes to the timing, cost, and success of clinical trials.
• The FDA may require additional clinical studies for the approval of Anaphylm.
• There is a risk that the FDA will not approve Libervant for U.S. market access due to orphan drug exclusivity.
• The company faces risks related to insufficient capital and cash resources to fund future clinical development activities.
• Aquestive faces the risk of eroding market share for Suboxone, which accounts for a substantial part of its current operating revenue.
• There are risks associated with intellectual property rights and infringement claims relating to the company's products.

Future Outlook

Aquestive expects total revenue between $48 million and $51 million and a non-GAAP adjusted EBITDA loss between $22 million and $26 million for 2024. The revenue guidance does not include any revenue for Libervant.

Management Comments

• We ended 2023 on a strong note with double digit base revenue growth, an improved balance sheet, and the start of our pivotal study for Anaphylm.
• We are now focused on continuing our progress in 2024 and building a strong foundation for the long-term growth of the Company.
• Anaphylm, as the only orally administered epinephrine product under development for the treatment of severe allergic reactions including anaphylaxis, continues to represent a transformational opportunity for both patients and the Company.

Industry Context

Aquestive is operating in the pharmaceutical industry, focusing on innovative drug delivery technologies. The company's focus on oral film technology for complex molecules positions it as a potential disruptor in the market. The development of Anaphylm, an orally delivered epinephrine product, addresses a significant unmet need in the treatment of anaphylaxis. The company's manufacturing capabilities and collaborations also place it in a competitive position within the pharmaceutical manufacturing sector.

Comparison to Industry Standards

• Aquestive's revenue growth of 26% (excluding the impact of prior year proprietary sales of Sympazan) is a strong performance compared to the average growth rate of many pharmaceutical companies.
• The significant reduction in non-GAAP adjusted EBITDA loss from $35.3 million to $11.6 million indicates improved operational efficiency and cost management.
• The company's focus on innovative drug delivery technologies, such as oral film, differentiates it from traditional pharmaceutical companies that rely on conventional delivery methods.
• The development of Anaphylm, an orally delivered epinephrine product, is a novel approach compared to the existing autoinjector market dominated by companies like Mylan (EpiPen) and Kaleo (Auvi-Q).
• The manufacturing volumes of approximately 45 million doses in Q4 2023 demonstrate Aquestive's capacity to meet the demands of its licensing and supply collaborations, which is comparable to other contract manufacturing organizations (CMOs) in the pharmaceutical sector.

Stakeholder Impact

• Shareholders will be impacted by the improved financial performance and progress in the company's pipeline.
• Employees will be impacted by the company's growth and future prospects.
• Patients will benefit from the potential approval of Anaphylm and Libervant.
• Customers and suppliers will be impacted by the company's manufacturing and supply collaborations.

Next Steps

• Aquestive will report topline data from the Anaphylm pivotal study in March 2024.
• The company anticipates an FDA decision on the Libervant application in April 2024.
• Aquestive plans to submit the Anaphylm NDA before the end of 2024.
• The company will continue to advance its pipeline assets utilizing its Adrenaverse technology.

Key Dates

Keywords

Aquestive Therapeutics, Anaphylm, Libervant, Epinephrine, Diazepam, Sublingual Film, Buccal Film, FDA, Clinical Trials, Pharmaceuticals, Revenue, EBITDA, Manufacturing, NDA, Orphan Drug Exclusivity